Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative intravenous ferric derisomaltose + erythropoietin + tranexamic acid vs conventional care in anemic or iron-deficient bone tumor surgery patients
ChiCTR2500108117Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose, erythropoietin and tranexamic acid in anaemia, iron deficiency anemia (IDA), bone cancer and 1 more (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Hemoglobin level 21 days after surgery. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ferric derisomaltoseerythropoietintranexamic acid
03
Conditions
anaemiairon deficiency anemia (IDA)bone cancerbone metastases
Beyond the preview
Go deeper on ChiCTR2500108117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108117.